Psoriasis

As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in psoriasis this year.

Experts discussed the challenges of managing GPP and highlight a pivotal study on the subcutaneous formulation of spesolimab, demonstrating its potential to prevent GPP flares and improve patient outcomes despite some limitations.

Michael Lewitt, MD, FAAD, highlighted the importance of personalized care, the decision-making process in psoriasis treatment, and the role of patient education.

Join Dermatology Times’ quarterly editor in chief Christopher Bunick, MD, PhD, as he discusses transformative advances in psoriasis care.

The adalimumab biosimilar had an average persistence of 2.5 years, according to this British study.

Researchers found two-thirds of patients reported no impact of psoriasis on their quality of life after 52 weeks of treatment with deucravacitinib.

The effect of insurance status on US patients with psoriasis can help identify those at risk of being undertreated.

Researchers found patients reporting greater disease burden and lower HRQoL are more likely to switch to biologic therapies, regardless of clinician-rated disease severity.

Diarrhea, nausea, and headache were the most frequently reported adverse events in psoriasis patients.

The exclusive event brought together physician assistants and nurse practitioners from across the country to review atopic dermatitis and psoriasis patient cases.

Researchers found patients treated with risankizumab had higher rates of skin clearance and greater improvement than those treated with deucravacitinib.

The FDA recently approved Yesintek for treating psoriasis, psoriatic arthritis, and IBD, with a 2025 launch expected.

If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.

Hawkes highlighted how second-generation TYK2 inhibitors improve upon earlier oral therapies with greater efficacy and selectivity.

Researchers found the TYK2 inhibitor deucravacitinib offers superior efficacy to apremilast and comparable outcomes to biologics.

The LIBERO study confirmed brodalumab is effective in managing psoriasis in patients over 100 kg, showing comparable long-term benefits in patients under 100 kg.

Benjamin Lockshin, MD, FAAD, discussed combining biologics with topical innovations like tapinarof and roflumilast to address plaque psoriasis treatment gaps.

The company’s phase 3 trials show JNJ-2113 significantly improves skin clearance and tolerability for patients with moderate to severe psoriasis.

November's cover feature highlights the revolutionary role of artificial intelligence in the development of zasocitinib for the treatment of psoriasis.

Higher stress hyperglycemia ratios are linked to elevated mortality risk in psoriasis, highlighting its systemic nature and need for intensive care.

4 case histories highlight the physical and psychosocial burden of generalized pustular psoriasis.

Deucravacitinib demonstrated significant efficacy and safety in treating moderate to severe scalp psoriasis, as shown in the PSORIATYK SCALP trial presented at Fall Clinical.

Joel Gelfand, MD, discusses insights on complex psoriasis cases, comorbidity management, and the evolving role of phototherapy at Fall Clinical 2024.

Phase 3b study showed promise in clearing moderate PsO in sensitive areas for patients unresponsive to topical treatments.

Del Rosso reviews numerous new and upcoming topical therapeutics and indications including ruxolitinib, tapinarof, and more.